Christy Jones - 29 Jan 2025 Form 3 Insider Report for Beta Bionics, Inc. (BBNX)

Role
Director
Signature
/s/ Stephen Feider , Attorney-in-Fact
Issuer symbol
BBNX
Transactions as of
29 Jan 2025
Net transactions value
$0
Form type
3
Filing time
29 Jan 2025, 21:41:41 UTC
Next filing
03 Feb 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding BBNX Director Stock Option (right to buy) 29 Jan 2025 Class B Common Stock 9,137 $7.51 Direct F1, F2
holding BBNX Director Stock Option (right to buy) 29 Jan 2025 Class B Common Stock 9,137 $7.51 Direct F2, F3
holding BBNX Directo Stock Option (right to buy) 29 Jan 2025 Class B Common Stock 48,730 $7.51 Direct F2, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to this option shall vest in 36 equal monthly installments measured from April 27, 2021.
F2 In accordance with the Issuer's Amended and Restated Certificate of Incorporation, the Issuer's outstanding shares of Class B Common Stock will convert into an equal number of shares of Common Stock immediately prior to the closing of the initial public offering.
F3 The shares subject to this option shall vest in 36 equal monthly installments measured from July 20, 2021.
F4 The shares subject to this option shall vest in 48 equal monthly installments measured from July 27, 2022.